Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease
Belite Bio has initiated a rolling submission of a New Drug Application to the FDA for tinlarebant as a treatment for Stargardt disease type 1, with completion expected in the second quarter of 2026. The submission utilizes the Breakthrough Therapy Designation and includes transformative data from the Phase 3 DRAGON trial.
Key figures
- Drug Name
- Tinlarebant
- Phase Of Trial
- Phase 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.